As noted previously, Opko and 19 other defendants, including Dr. Phillip Frost, its CEO and chairman, were named in a complaint filed on September 7 by the Securities and Exchange Commission.
The company will vigorously defend itself against these charges.
As noted previously, the SEC's lawsuit does not contain any allegations about OPKO's financial practices, financial statements or business practices.
Opko Health is a healthcare company. In diagnostics, its BioReference Laboratories is the nation's third largest clinical laboratory; GeneDx is a genetic testing business; the 4Kscore prostate cancer test is used to confirm an elevated PSA to help decide about next steps such as prostate biopsy; Claros 1 is a point of care diagnostics platform with PSA and testosterone as the most advanced in development.
In its pharmaceutical pipeline, Rayaldee is Opko's first pharmaceutical product to be marketed.
OPK88003, a once weekly oxyntomodulin for type 2 diabetes and obesity in Phase 2 clinical trials, is among a new class of GLP-1 glucagon receptor dual agonists.
OPK88004, a SARM (Selective Androgen Receptor Modulator) for treating BPH (Benign Prostatic Hypertrophy), urinary incontinence and other conditions is in clinical trials.
The company's most advanced product utilizing its CTP technology, a once-weekly human growth hormone for injection, is in Phase 3 trials and is partnered with Pfizer.
Opko has research, development, production and distribution facilities abroad.
Zydus enters exclusive talks to acquire majority stake in Amplitude Surgical
Adcendo's ADCE-T02 Phase I study IND application receives US FDA approval
WHO grants Actinogen Medical's Xanamem/UE2343 non-proprietary name 'emestedastat'
IVFMD physicians named 2025 Castle Connolly Top Doctors
HOPE Therapeutics and NRx Pharmaceuticals select BTIG as financial advisor
Partillion Bioscience opens pre-orders for Nanovial Multicell Assay Antibody Discovery Kits
Champions Oncology expands bioanalytical services with new technology
Petauri's Nicole Lodowski named to MM+M's 40 Under 40 for 2025
WuXi XDC Cayman wins 'Best CDMO' at World ADC Awards 2024
Nektar Therapeutics agrees sale of Huntsville manufacturing facility and reagent supply business